vDOT + Financial Incentives for Latent Tuberculosis
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, you must be prescribed specific TB treatments to participate.
What data supports the effectiveness of the treatment Video Directly Observed Therapy (vDOT) with Financial Incentives for Latent Tuberculosis?
Research shows that Video Directly Observed Therapy (vDOT) is as effective as in-person observation for tuberculosis treatment, with high rates of treatment completion and patient satisfaction. It is also more convenient and cost-effective, making it a promising alternative to traditional methods.12345
Is Video Directly Observed Therapy (vDOT) safe for humans?
How does the vDOT with financial incentives treatment for latent tuberculosis differ from other treatments?
The vDOT with financial incentives treatment for latent tuberculosis is unique because it uses video technology to allow patients to take their medication remotely while being observed, which is more convenient and less costly than traditional in-person observation. Additionally, offering financial incentives can further encourage patients to adhere to their treatment schedule, potentially improving treatment outcomes.13578
What is the purpose of this trial?
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.
Research Team
Maunank Shah, MD, PhD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for adults over 18 living in the Baltimore area, diagnosed with latent tuberculosis and prescribed specific treatments (Isoniazid/Rifapentine, Isoniazid/Rifampin, or Rifampin). Participants must speak English/Spanish or a language supported by consent forms. Pregnant women, those under 18, with active TB, or on alternative treatments are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive treatment for latent tuberculosis using Video Directly Observed Therapy (vDOT) with or without financial incentives
Follow-up
Participants are monitored for treatment completion and adherence using MEMS caps and video observation
Treatment Details
Interventions
- Usual Care
- Video Directly Observed Therapy alone
- Video Directly Observed Therapy plus Financial Incentives
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator